Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
BackgroundCeftazidime-avibactam (CAZ-AVI) is a novel antibiotic that has been confirmed in the United States and China for use in patients with carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection (BSI). However, the cost-effectiveness of CAZ-AVI is unknown in China. This study ai...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Frontiers Media S.A.,
2023-02-01T00:00:00Z.
|
| Teme: | |
| Online pristup: | Connect to this object online. |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Primjerak 1 | Dostupno |